On Monday, Scotiabank (TSX:) updated its outlook on Vertex Pharmaceuticals (NASDAQ:) Incorporated, raising its price target slightly from $426 to $430 while maintaining a Sector Perform rating. The $102 billion biotech giant, currently trading at $397.27, appears slightly undervalued according to InvestingPro analysis. This adjustment follows the recent FDA approval of Vertex’s cystic fibrosis treatment, […]

On Monday, Baird took a revised stance on Nike Inc. (NYSE: NYSE:), adjusting the company’s price target to $105 from the previous $110 while continuing to endorse an Outperform rating on the stock. The firm’s analysis follows the recent earnings report where Nike’s second fiscal quarter earnings per share (EPS) outperformed the consensus estimates by

On Monday, Scotiabank (TSX:) increased its price target for Altius Minerals Corp (ALS:CN) (OTC: ATUSF) to C$33.00, up from C$27.00, and shifted the stock’s rating to Sector Outperform from Sector Perform. The revision reflects an anticipated positive return of over 29% to the new 12-month target price. The stock, currently valued at $838.45 million by

On Monday, BMO Capital Markets adjusted its stance on Novo Nordisk (NYSE:) shares following the release of Phase 3 clinical trial results for the company’s diabetes treatment, CagriSema. The price target for the pharmaceutical giant’s stock, which has seen a sharp 21% decline over the past week according to InvestingPro data, was reduced to $105.00

On Monday, BMO Capital Markets adjusted its outlook on FactSet Research Systems (NYSE:FDS), a provider of financial information and analytics software to the investment community. The firm’s analyst has lowered the price target on the stock to $518 from the previous $521, while the Market Perform rating remains unchanged. Currently trading at $483.52, the stock

On Monday, Oppenheimer has adjusted its financial model for Integer Holdings Corporation (NYSE: NYSE:), resulting in a revised price target. The firm now values the medical device outsource manufacturer at $138.00, increased from the previous $135.00, while maintaining an Outperform rating on the stock. The target adjustment comes as ITGR trades near its 52-week high

On Monday, Loop Capital raised the price target for Ollie’s Bargain Outlet (NASDAQ: OLLI) shares to $130 from the previous $120, while maintaining a Buy rating on the stock. Currently trading at $117.91, OLLI has demonstrated remarkable momentum with a 64.4% return over the past year. The adjustment follows a recent visit by the firm’s

On Monday, Morgan Stanley (NYSE:) reiterated its Overweight rating on Fujifilm Holdings Corp. (TYO::JP) (OTC: FUJIY), with a price target of JPY4,200.00. The firm’s analysis suggests that Fujifilm’s growth narrative, driven by its healthcare-related earnings, remains solid. However, it anticipates a temporary deceleration in profit growth for the fiscal year ending March 2026 (F3/26) due

On Monday, H.C. Wainwright reaffirmed its Buy rating and $16.00 price target for BrainsWay (NASDAQ:BWAY), highlighting recent favorable clinical data. The stock, currently trading at $9.24, has shown strong momentum with a 50% price return over the past six months. According to InvestingPro data, the company maintains excellent financial health with a “GREAT” overall score,

On Monday, H.C. Wainwright maintained its Buy rating and $8.00 price target for InflaRx NV (NASDAQ:), currently trading at $2.24, following the company’s announcement on December 20 about the commencement of a Phase 2a basket study for its drug candidate INF904. According to InvestingPro data, analysts maintain a strong bullish consensus with price targets ranging